Innate Pharma schedules August 14 investor webcast
Innate Pharma S.A. reports that it will host a conference call and live webcast on August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
Innate Pharma S.A. reports that it will host a conference call and live webcast on August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT. The event will feature CEO Jonathan Dickinson, COO Yannis Morel, CFO Frédéric Lombard and VP Investor Relations Stéphanie Cornen.
The webcast link and telephone registration are provided, and a replay will be available on the company’s website. Innate describes itself as a global, clinical-stage biotechnology company focused on cancer immunotherapies, with a proprietary pipeline centered on antibody-drug conjugates and partnered late-stage assets in cutaneous T-cell lymphomas and non-small cell lung cancer.
Key Figures
Conference call date: August 14, 2026
Conference call time CEST: 2:00 p.m. CEST
Conference call time EDT: 8:00 a.m. EDT
+2 more
5 metrics
Conference call date
August 14, 2026
Scheduled date of investor conference call and webcast
Conference call time CEST
2:00 p.m. CEST
Scheduled start time of the call in Central European Summer Time
Conference call time EDT
8:00 a.m. EDT
Scheduled start time of the call in U.S. Eastern Daylight Time
Lead ADC asset
IPH4502
Differentiated Nectin-4 antibody-drug conjugate in clinical development for solid tumors
ISIN code
FR0010331421
Identification code for Innate Pharma shares
Key Terms
antibody-drug conjugates (ADCs), Nectin-4, non-small cell lung cancer (NSCLC), clinical-stage biotechnology, +2 more
6 terms
antibody-drug conjugates (ADCs) medical
"Its proprietary pipeline is centered on antibody-drug conjugates (ADCs), led by IPH4502"
Antibody-drug conjugates (ADCs) are advanced medicines that combine a targeted antibody with a powerful drug, acting like a guided missile to deliver treatment directly to cancer cells while sparing healthy tissue. This precision approach can improve effectiveness and reduce side effects, making ADCs a promising area of biotech innovation. For investors, advancements in ADC technology can signal potential growth opportunities in the pharmaceutical and healthcare sectors.
Nectin-4 medical
"IPH4502, a differentiated Nectin-4 ADC in clinical development for solid tumors"
A cell-surface protein that helps neighboring cells stick together and communicate; it is normally present during development but can become abundant on certain cancer cells. Investors pay attention because high levels make it a useful biomarker and a direct target for cancer therapies and diagnostic tests—similar to a distinctive flag on a building that lets a targeted treatment or test find and act on diseased tissue—affecting drug value, regulatory reviews, and market potential.
non-small cell lung cancer (NSCLC) medical
"monalizumab, developed with AstraZeneca for non-small cell lung cancer (NSCLC)"
A common group of lung cancers that arise from the lungs’ cell lining and grow in ways different from the faster-spreading “small cell” form; think of it as several related varieties of the same illness rather than one single disease. It matters to investors because diagnosis rates, new drugs, diagnostic tests, and clinical trial results for these cancers can drive large, sustained revenue opportunities and regulatory decisions that materially affect healthcare and biotech company valuations.
clinical-stage biotechnology medical
"Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies"
Clinical-stage biotechnology refers to biotechnology companies that are in the process of testing new medical treatments or drugs in human trials. This stage is crucial because it indicates that these treatments have shown enough promise in earlier research to be evaluated for safety and effectiveness in people. For investors, it signals a key phase where potential breakthroughs are being tested, but also involves higher risk since the outcomes are still uncertain.
immunotherapies medical
"biotechnology company developing immunotherapies for cancer patients"
Immunotherapies are medical treatments that strengthen or guide the body's own immune system to recognize and fight disease cells, such as cancer or chronic infections. They matter to investors because they can produce long-lasting patient responses, command premium prices, and reshape standard care—similar to installing a smarter security system that prevents repeat break-ins—creating significant commercial upside but also clinical and regulatory risk.
cutaneous T-cell lymphomas medical
"lacutamab, developed with Sobi for cutaneous T-cell lymphomas"
A group of rare non-Hodgkin lymphomas in which cancerous T-lymphocytes primarily grow in the skin, causing patches, plaques, nodules or tumors and sometimes spreading internally. Investors care because these chronic, often slow-progressing diseases create specialized markets for diagnostics, topical and systemic therapies, and clinical trials; trial results, regulatory decisions, and new treatment approvals can materially affect companies focused on cancer drugs and dermatology.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is Innate Pharma (IPHA) hosting its next conference call?
Innate Pharma will host a conference call on August 14, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT. The event will be accessible via webcast and telephone, with a replay available on the company’s website.
How can investors access Innate Pharma (IPHA)'s August 14, 2026 webcast?
Investors can access the live webcast via the provided Q4 Inc. webcast link and register for telephone access through a separate Q4 registration link. A replay will later be posted in the Investors section of Innate Pharma’s website.
Which Innate Pharma (IPHA) executives will speak on the August 14, 2026 call?
Speakers will include CEO Jonathan Dickinson, COO Yannis Morel, CFO Frédéric Lombard and VP Investor Relations Stéphanie Cornen. They will represent management and investor relations during the conference call and webcast.
What does Innate Pharma (IPHA) focus on in its biotechnology pipeline?
Innate Pharma focuses on immunotherapies for cancer, emphasizing antibody-drug conjugates (ADCs) such as IPH4502 targeting Nectin-4, along with partnered late-stage assets lacutamab and monalizumab for cutaneous T-cell lymphomas and non-small cell lung cancer.
Who should investors and media contact at Innate Pharma (IPHA)?
Investors can contact Investor Relations at investors@innate-pharma.fr, while media requests go to communication@innate-pharma.fr. Dedicated contact for Investors & Media Relations is Stéphanie Cornen at stephanie.cornen@innate-pharma.fr.
AI-generated analysis. How Rhea-AI works. Not financial advice.
